Last reviewed · How we verify
NCT04648293
Starling Registry Study
trial testing Starling in Hemodynamic Monitoring in 1,207 participants. Completed in 21 February 2024.
21 February 2024
Quick facts
| Lead sponsor | Baxter Healthcare Corporation |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,207 |
| Start date | 16 November 2020 |
| Primary completion | 21 February 2024 |
| Estimated completion | 21 February 2024 |
| Sites | 9 locations across United States |
Drugs / interventions tested
- Starling
Conditions studied
- Hemodynamic Monitoring — all drugs for Hemodynamic Monitoring →
Sponsor
Baxter Healthcare Corporation — full company profile →
Who can join
Adults 18 to 95, any sex, with Hemodynamic Monitoring. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hemodynamic optimization of critically ill patients is a goal for clinicians in order to afford the patient the best possible outcomes. Being able to precisely and rapidly determine patient fluid responsiveness provides the bedside physician and nursing staff the information needed to make critical decisions in regards to the patient's fluid status and management of additional fluids and medications. As fluid management and cardiac output determination are linked to better decision-making and improved outcomes in ICU, the use of a dynamic assessment of fluid responsiveness becomes a key tool for patient management. This study is designed to collect treatment and outcome data on patients that have undergone hemodynamic monitoring in a wide variety of clinical settings, involving a variety of patient diagnoses.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
ESICM LIVES 2022: part 2.
· 2022 · cited 3× · PMID 36258052 · DOI 10.1186/s40635-022-00469-0 -
42nd International Symposium on Intensive Care & Emergency Medicine
· 2023 -
41st International Symposium on Intensive Care and Emergency Medicine
· 2022
Verify or expand the search:
- PubMed search for NCT04648293
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Starling
Trials testing the same drug.
- NCT05729048 — Starling/CRRT Observational Study · withdrawn
Other recruiting trials for Hemodynamic Monitoring
Currently open trials in the same condition.
- NCT07396636 — Machine Learning-Assisted Management of Intraoperative Hypotension for Personalized Treatment · recruiting
- NCT07062744 — The Role of Swan-Ganz Catheter in Hemodynamic Resuscitation for Patients With Cardiogenic Shock · NA · recruiting
- NCT06918301 — Comparison of Cardiac Index and Stroke-volume-index Measured by Pulmonary Artery Catheter, FloTrac® and Argos® in Cardia · recruiting
- NCT07270341 — Evaluation of Cerebral Oxygenation During Orthopedic Surgeries Performed in the Beach Chair Position Under General Anest · recruiting
- NCT04281771 — Assessment of Paravalvular Leak After TAVI by Hemodynamic Measurements and Cardiac MRI · NA · active not recruiting
Other Baxter Healthcare Corporation trials
Trials by the same sponsor.
- NCT07256951 — Gen 2 Battrode Wear Study · NA · recruiting
- NCT07158333 — Mobile Cardiac Telemetry (MCT) Study · completed
- NCT06842121 — A Bioequivalence Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Inorganic Phosphate (Sodium Ph · Phase 1 · completed
- NCT06842134 — A Study Comparing Organic Phosphate (Sodium Glycerophosphate Injection) to Numeta G16%E · Phase 1 · completed
- NCT05996809 — PMCF Study for COSEAL® in Gynecologic Surgery · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04648293 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Baxter Healthcare Corporation
- Last refreshed: 16 April 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04648293.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing